Product News

Share this article:
Watson received FDA approval for a generic version of Plan B, Duramed Pharmaceuticals' emergency contraceptive. Watson's generic is approved for prescription only, in women 17 and younger. Duramed retains OTC exclusivity on the product – indicated for women 18 years and older – until August 24, 2009.

FDA did not approve GlaxoSmithKline's Rexonic (casopitant mesylate), an antiemetic. FDA issued a complete response letter containing questions that “preclude the approval of the application,” according to a GSK statement. “[GSK] is reviewing this letter and will engage FDA to determine appropriate next steps,” the statement said.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.